obesity

Novo Nordisk posts 'best-case scenario' cardio outcomes data for star obesity drug Wegovy
Fierce Pharma
Tue, 08/8/23 - 11:25 am
Novo Nordisk
Wegovy
clinical trials
cardiovascular disease
obesity
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Lilly's obesity drug leads to about 26% weight loss in new studies
Yahoo/Reuters
Thu, 07/27/23 - 11:41 am
Eli Lilly
obesity
clinical trials
Mounjaro
Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval
Fierce Pharma
Wed, 07/26/23 - 11:26 am
Eli Lilly
Mounjaro
obesity
weight loss
drug shortages
Novo Nordisk, Eli Lilly and Boehringer Ingelheim back bill to bring obesity drug coverage to Medicare
Fierce Pharma
Thu, 07/20/23 - 09:42 pm
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
obesity
Novartis axes secretive obesity program after high-risk, high-reward bet fails
Fierce Biotech
Tue, 07/18/23 - 11:41 am
Novartis
obesity
pancreatic cancer
Hungry for more, Lilly tops off weight loss pipeline with $1.9B deal to acquire Versanis
Fierce Biotech
Fri, 07/14/23 - 10:10 am
Eli Lilly
M&A
obesity
Versanis
bimagrumab
Pharma finds a way to gain weight
EP Vantage
Thu, 07/13/23 - 09:49 am
obesity
Eli Lilly
Novo Nordisk
Wegovy
Mounjaro
Why Novo Nordisk Stock Sank on Tuesday
Motley Fool
Tue, 07/11/23 - 11:23 pm
Novo Nordisk
obesity
Wegovy
Ozempic Sales Are Soaring -- Here's Why They Could Go Even Higher
Motley Fool
Thu, 07/6/23 - 11:17 am
Novo Nordisk
Ozempic
obesity
diabetes
weight loss
addiction
Pfizer Just Canned One of Its Ozempic Killers. What's Next?
Motley Fool
Mon, 07/3/23 - 10:37 am
Pfizer
obesity
lotiglipron
danuglipron
Novo Nordisk
Eli Lilly
Ozempic
Mounjaro
Obesity: Six trials to watch over the next 12 months
Clinical Trials Arena
Fri, 06/30/23 - 11:45 am
obesity
clinical trials
Novo Nordisk
Altimmune
Innovent Biologics
Pfizer
Shionogi
Tonix
semaglutide
oxytocin
permvidutide
mazdutide
danuglipron
ADA 2023 – Lilly unveils its triple threat
EP Vantage
Wed, 06/28/23 - 09:57 am
Eli Lilly
Novo Nordisk
retatrutide
Wegovy
Mounjaro
obesity
clinical trials
Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle
Fierce Biotech
Mon, 06/26/23 - 10:00 am
Eli Lilly
obesity
orforglipron
Pfizer
Novo Nordisk
Mounjaro
Pfizer, citing safety concerns, scraps one of two obesity pill hopefuls
BioPharma Dive
Mon, 06/26/23 - 09:57 am
Pfizer
obesity
lotiglipron
danuglipron
Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect
Fierce Biotech
Sun, 06/25/23 - 09:46 pm
Boehringer Ingelheim
obesity
clinical trials
Zealand Pharma
survodutide
Novo Nordisk says EMA raised safety signal on drugs including semaglutide
Yahoo/Reuters
Thu, 06/22/23 - 10:21 am
Novo Nordisk
EMA
semaglutide
Ozempic
Wegovy
thyroid cancer
obesity
diabetes
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
EP Vantage
Wed, 06/21/23 - 10:38 am
ADA
Eli Lilly
Pfizer
diabetes
obesity
orforglipron
danuglipron
lotiglipron
Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo: report
Fierce Pharma
Mon, 06/19/23 - 10:29 am
Eli Lilly
Novo Nordisk
Mounjaro
semaglutide
diabetes
obesity
This Biotech Is Developing The Next Ozempic
Motley Fool
Fri, 06/16/23 - 10:11 am
Structure Therapeutics
diabetes
obesity
Ozempic

Pages